<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01196455</url>
  </required_header>
  <id_info>
    <org_study_id>MO18646</org_study_id>
    <nct_id>NCT01196455</nct_id>
  </id_info>
  <brief_title>Capecitabine and Mitomycin C in Treatment of Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Clinical Study of Capecitabine in Combination With Mitomycin C as First-Line Treatment in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Croatian Cooperative Group for Clinical Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Croatian Cooperative Group for Clinical Research in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, non-comparative efficacy and safety study of Capecitabine and&#xD;
      Mitomycin C as first-line treatment in patients with previously untreated metastatic breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>average 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>time to disease progression</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Mitomycin C</intervention_name>
    <description>Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks&#xD;
Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks</description>
    <other_name>Capecitabine (Xeloda)</other_name>
    <other_name>Mitomycin C (Mutamycin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically/cytologically confirmed breast cancer&#xD;
&#xD;
          -  Metastatic breast cancer, having at least one target lesion according to the RECIST&#xD;
             criteria. Bone metastases, leptomeningeal disease, ascites, pleural or pericardial&#xD;
             effusions, inflammatory breast disease, lymphangitic spread or cystic lesions are not&#xD;
             acceptable as target lesions. Target lesions must be ≥ 10 mm longest diameter measured&#xD;
             in one dimension using spiral CT, or ≥ 20 mm longest diameter measured in one&#xD;
             dimension using conventional techniques. In addition to the definitions pertaining to&#xD;
             the target lesion(s) from the RECIST criteria above, the target lesion(s) must not&#xD;
             have been previously irradiated (newly arising lesions in previously irradiated areas&#xD;
             are acceptable).&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Signed informed consent obtained prior to initiation of any study-specific procedures&#xD;
             or treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior cytotoxic chemotherapy or active/passive immunotherapy for metastatic breast&#xD;
             disease&#xD;
&#xD;
          -  Prior usage of capecitabine or mitomycin as adjuvant or neoadjuvant treatment&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Not-ambulatory or with an ECOG performance status &gt; 1&#xD;
&#xD;
          -  Insufficient hematological, renal and hepatic functions:&#xD;
&#xD;
          -  hemoglobin &lt; 8.0 g/dL&#xD;
&#xD;
          -  absolute neutrophils count (ANC) &lt; 1.5 x 109/L&#xD;
&#xD;
          -  platelet count &lt; 100 x 109/L&#xD;
&#xD;
          -  serum creatinine &gt; 1.25 x N*&#xD;
&#xD;
          -  total bilirubin &gt; 2.0 x N*&#xD;
&#xD;
          -  ASAT and/or ALAT &gt; 2.5 x N* (in case of liver metastases &gt; 5 x N*)&#xD;
&#xD;
          -  alkaline phosphatase &gt; 2.5 x N* (in case of liver metastases &gt; 5 x N*, in case of bone&#xD;
             metastases &gt; 10 x N*) *N = upper limit of standard range&#xD;
&#xD;
          -  Severe renal impairment [creatinine clearance &lt; 30 mL/min (calculated according to&#xD;
             cockcroft and Gault)]&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Vrdoljak, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Split, Center of oncology, Croatia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eduard Vrdoljak, PhD MD</last_name>
    <phone>00385-21-556-129</phone>
    <email>eduard.vrdoljak@st.htnet.hr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center of oncology</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Vrdoljak, MD PhD</last_name>
      <phone>00385-21-556-129</phone>
      <email>eduard.vrdoljak@st.htnet.hr</email>
    </contact>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>August 31, 2010</study_first_submitted>
  <study_first_submitted_qc>September 7, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2010</study_first_posted>
  <last_update_submitted>September 7, 2010</last_update_submitted>
  <last_update_submitted_qc>September 7, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. sc. Eduard Vrdoljak</name_title>
    <organization>Clinical Hospital Split, Center of oncology</organization>
  </responsible_party>
  <keyword>Metastatic breast cancer patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

